IMNN

SEC Filing Summary: Celsion Corporation (10-Q)

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for Celsion Corporation for the period ended March 31, 2009. Celsion is an oncology drug development company focused on heat-activated liposomal technology. Its lead product, ThermoDox, is in Phase III trials for primary liver cancer and Phase II trials for recurrent chest wall breast cancer. The company has no product revenues and relies on equity sales and divestitures to fund operations.

Key Financial Metrics

Liquidity Note: The company holds a significant receivable of $15,000,000 due from Boston Scientific Corporation, expected to be received in June 2009. Total liquid resources (cash, investments, and receivable) are approximately $19.3 million.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $465,000 (11.4%) compared to Q1 2008, primarily driven by a significant reduction in General and Administrative (G&A) expenses.
• G&A Expenses: Decreased by $488,000 (41.5%). This was largely due to a $680,000 write-down of a note receivable recognized in Q1 2008 that did not recur in 2009. This decrease was partially offset by increased business development costs and G&A salaries.
• R&D Expenses: Remained relatively flat, decreasing slightly by $24,000 (0.8%). Increased costs for breast cancer trials were offset by decreased costs for liver cancer trials.
• Interest Income: Decreased by $55,000 due to lower interest rates on investments.
• Cash Position: Cash and cash equivalents decreased by $1.5 million during the quarter due to operating cash outflows of $3.1 million, partially offset by net cash provided by investing activities ($1.7 million) from the sale of short-term investments.

Outlook, Risks, and Management Commentary

• Capital Resources: Management expects current cash resources ($19.3 million) to be adequate to fund operations through mid-2010. However, substantial additional capital will be required to complete clinical trials, obtain marketing approvals, and commercialize products.
• Key Contingency: The company's liquidity is heavily dependent on the $15 million receivable from Boston Scientific. A default by Boston Scientific would necessitate immediate additional funding, which is not currently committed.
• Risk Factors:
  • History of Losses: The company has an accumulated deficit of $70.5 million and expects to continue incurring losses until products are approved and marketed.
  • Regulatory Approval: Success depends on FDA and foreign regulatory approvals, which are uncertain and costly.
  • Third-Party Reliance: The company relies entirely on third-party Clinical Research Organizations (CROs) for clinical trials and lacks internal sales/marketing capabilities.
  • Licensing Risks: The business depends on license agreements with Duke University and others; failure to meet milestones could result in loss of rights.
• Unusual Items: No unusual items were reported for Q1 2009. The significant non-cash item in the prior year (note receivable write-down) was not present in the current period.

Investor Verification Checklist

• Verify the status and expected payment date of the $15 million receivable from Boston Scientific, as this is critical to the company's runway through mid-2010.
• Confirm the progress and enrollment status of the Phase III liver cancer trial and Phase II breast cancer trial for ThermoDox.
• Review the terms of the licensing agreement with Yakult Honsha regarding the $18 million potential milestone payments for Japanese market approval.
• Assess the company's ability to raise additional capital if the Boston Scientific payment is delayed or if clinical trial costs exceed projections.
• Monitor the stock-based compensation expense, which totaled nearly $300,000 for the quarter, and the remaining unrecognized cost of $2.0 million.